JPH01172330A - Preventive and remedy for infectious disease of salmonella typhimurium of mammals and birds - Google Patents
Preventive and remedy for infectious disease of salmonella typhimurium of mammals and birdsInfo
- Publication number
- JPH01172330A JPH01172330A JP62328333A JP32833387A JPH01172330A JP H01172330 A JPH01172330 A JP H01172330A JP 62328333 A JP62328333 A JP 62328333A JP 32833387 A JP32833387 A JP 32833387A JP H01172330 A JPH01172330 A JP H01172330A
- Authority
- JP
- Japan
- Prior art keywords
- gobaishi
- birds
- mammals
- preventive
- salmonella typhimurium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003449 preventive effect Effects 0.000 title claims abstract description 13
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 title claims description 21
- 241000124008 Mammalia Species 0.000 title claims description 20
- 208000015181 infectious disease Diseases 0.000 title claims description 19
- 208000035473 Communicable disease Diseases 0.000 title description 3
- 239000003814 drug Substances 0.000 claims abstract description 19
- 239000003960 organic solvent Substances 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 10
- 241000271566 Aves Species 0.000 claims description 18
- 229940124597 therapeutic agent Drugs 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- 241000283690 Bos taurus Species 0.000 claims description 8
- 230000000069 prophylactic effect Effects 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 241000282887 Suidae Species 0.000 claims description 5
- 241000287828 Gallus gallus Species 0.000 claims description 4
- 235000013330 chicken meat Nutrition 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 241000699670 Mus sp. Species 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims 2
- 241000894006 Bacteria Species 0.000 abstract description 8
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 229940074391 gallic acid Drugs 0.000 abstract description 3
- 235000004515 gallic acid Nutrition 0.000 abstract description 3
- 239000003925 fat Substances 0.000 abstract description 2
- 239000011347 resin Substances 0.000 abstract description 2
- 229920005989 resin Polymers 0.000 abstract description 2
- 229920001864 tannin Polymers 0.000 abstract description 2
- 239000001648 tannin Substances 0.000 abstract description 2
- 235000018553 tannin Nutrition 0.000 abstract description 2
- 244000144994 Galla Rhois Species 0.000 abstract 3
- 240000003152 Rhus chinensis Species 0.000 abstract 1
- 235000014220 Rhus chinensis Nutrition 0.000 abstract 1
- 235000010889 Rhus javanica Nutrition 0.000 abstract 1
- 241001516602 Schlechtendalia chinensis Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 241000411851 herbal medicine Species 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 241000607142 Salmonella Species 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- -1 n -Propertool Chemical compound 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241001124076 Aphididae Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- APQIUTYORBAGEZ-UHFFFAOYSA-N 1,1-dibromoethane Chemical compound CC(Br)Br APQIUTYORBAGEZ-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000003910 Baronia <angiosperm> Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241000272194 Ciconiiformes Species 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000721570 Melaphis Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010033971 Paratyphoid fever Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000021735 chronic enteritis Diseases 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 239000000321 herbal drug Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は、哺乳類および鳥類のサルモネラ・ティフィム
リウム感染症の予防及び治療剤並びに予防及び治療方法
に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present invention relates to preventive and therapeutic agents and methods for preventing and treating Salmonella typhimurium infections in mammals and birds.
さらに詳しくは、哺乳類および鳥類のサルモネラ・ティ
フィムリウム感染度の生薬含有予防及び治療剤並びに生
薬を投与することからなる予防及び治療方法に関する。More specifically, the present invention relates to a prophylactic and therapeutic agent containing a herbal medicine for the degree of Salmonella typhimurium infection in mammals and birds, and a preventive and therapeutic method comprising administering the herbal medicine.
［従来の技術］
サルモネラ・ティフィムリウム感染症は、サルモネラ属
の細菌に起因するサルモネラ症のうちサルモネラ・ティ
フィムリウムＳａ１ｍｏｎｅｌｌａ ｔｙｐｈＩｍｕｒ
ｌｕｍに起因するものであって、パラチフスとよばれる
場合もある。[Prior Art] Salmonella typhimurium infection is Salmonella typhimurium among salmonellosis caused by bacteria of the genus Salmonella.
lum, and is sometimes called paratyphoid fever.
牛、豚、マウス等の哺乳類や鶏、鳩、サギ等の鳥類に見
られる疾病である。It is a disease seen in mammals such as cows, pigs, and mice, and birds such as chickens, pigeons, and herons.
牛の場合には、水様下痢または粘血便を***し、ときに
は肺炎症状を伴い１〜７日の経過で敗血症死するが、慢
性例では関節炎、脳炎等の症状を呈することがある。In the case of cattle, they excrete watery diarrhea or mucus-bloody stools, sometimes accompanied by pneumonia symptoms, and die from sepsis in 1 to 7 days, but chronic cases may exhibit symptoms such as arthritis and encephalitis.
豚の場合には、一般的には急性敗血症型や慢性腸炎型の
２つの病型として認められ、前者ではほとんどのものが
死亡し、後者でも病気の経過とともに豚の経済的価値が
失なわれる。鶏の場合には、卿化後１０日以内に発症し
て、元気喪失、白色下痢側、関節炎、盲目症が発生し、
死亡することが多い。In the case of pigs, two types of disease are generally recognized: acute sepsis type and chronic enteritis type; in the former, most animals die, and in the latter, the economic value of pigs is lost as the disease progresses. . In the case of chickens, the disease develops within 10 days after becoming infected, and symptoms include loss of energy, white diarrhea, arthritis, and blindness.
Death is common.
発生率が高く、裕度経営上、被害の大きい疾病の１つと
されている。・また、肉用動物では、人への感染源とも
なりつるので公衆衛生の面からも重要な問題とされてい
る。It is considered to be one of the diseases that has a high incidence and causes great damage in terms of economic management.・Also, meat animals are considered to be an important issue from a public health perspective, as they can be a source of infection for humans.
このような重大な伝染病であるにもかかわらず、有効な
対策はほとんどなく、適切な飼育管理を行なうことなど
の対策がとられているが、実際には予防できないことが
多い。Despite the fact that it is such a serious infectious disease, there are almost no effective countermeasures, and although measures such as proper breeding management are taken, in reality it is often impossible to prevent it.
また、これまでに本疾病を予防及び治療するために、例
えば抗生物質やその他の抗菌剤を飼料と共に投与する方
法も行なわれている。しかし、近年特に耐性菌の発生や
動物への抗生物質等の残留性の問題等があって、抗生物
質等の投与を哺乳類および鳥類に対して行なうことは適
当でないという気運が高まりつつある。従って、抗生物
質などを用いない水痘の予防及び治療方法と予防及び治
療剤の開発が望まれている。Furthermore, in order to prevent and treat this disease, for example, methods have been used in which antibiotics and other antibacterial agents are administered together with feed. However, in recent years, there has been a growing trend that it is not appropriate to administer antibiotics to mammals and birds, especially due to problems such as the occurrence of resistant bacteria and the persistence of antibiotics in animals. Therefore, it is desired to develop methods and agents for preventing and treating chickenpox that do not use antibiotics or the like.
［問題点を解決するための手段］
本発明者らは、上記の問題点を解決すべく研究した結果
、生薬ゴバイシに本疾病を抑制する効果がある事を見出
し、本発明を完成させた。[Means for Solving the Problems] As a result of research to solve the above problems, the present inventors discovered that the herbal drug Gobaishi has the effect of suppressing this disease, and completed the present invention.
即ち、本発明の目的は、哺乳類および鳥類のサルモネラ
・ティフィムリウム感染症の予防及び治療剤並びに同区
の予防及び治療方法を提供することにある。That is, an object of the present invention is to provide a preventive and therapeutic agent for Salmonella typhimurium infection in mammals and birds, and a method for preventing and treating the same.
本発明は、ゴバイシを含有する哺乳類および鳥類のサル
モネラ・ティフィムリウム感染症の予防及び治療剤を提
供するものである。The present invention provides a preventive and therapeutic agent for Salmonella typhimurium infection in mammals and birds, which contains Gobaishi.
本発明は、また原末の形態のゴバイシ、有機溶剤、有機
溶剤と水との混合物または水で抽出して得られるゴバイ
シエキス、またはゴバイシ有効成分を含有する上記の哺
乳類および鳥類のサルモネラ、ティフィムリウム感染症
の予防及び治療剤を提供するものである。The present invention also provides for Salmonella Typhimurium in the form of bulk powder, Salmonella Typhimurium, an organic solvent, a mixture of an organic solvent and water, or a Salmonella Typhimurium extract of mammals and birds containing the active ingredient of Salmonella Typhimurium. The present invention provides a preventive and therapeutic agent for infectious diseases.
本発明はまたゴバイシを飼料中に配合してなる哺乳類お
よび鳥類のサルモネラ・ティフィムリウム感染症の予防
及び治療剤を提供するものである。The present invention also provides a preventive and therapeutic agent for Salmonella typhimurium infection in mammals and birds, which is prepared by incorporating Gobaishi in feed.
更に本発明は、有効量のゴバイシを投与することからな
る哺乳類および鳥類のサルモネラ・ティフィムリウム感
染症の予防及び治療方法を提供するものである。Further, the present invention provides a method for preventing and treating Salmonella typhimurium infections in mammals and birds, which comprises administering an effective amount of Gobaishi.
本発明はまた、原末の形態のゴバイシ、有機溶剤、有機
溶剤と水との混合物または水で抽出して得られるゴバイ
シエキス、またはゴバイシ有効成分の形態で投与するこ
とからなる曙乳類および鳥類のサルモネラ・ティフィム
リウム感染症の予防及び治療方法を提供するものである
。The present invention also provides for the treatment of mammals and birds, which is administered in the form of a bulk powder, a Gobaishi extract obtained by extraction with an organic solvent, a mixture of an organic solvent and water, or water, or an active ingredient of Gobaishi. Provided are methods for preventing and treating Salmonella typhimurium infections.
ゴバイシ（五倍子）は、ヌルデノミミフシアブラムシ（
Ｍｅｌａｐｈｉｓ ｃｈｔｎｅｎｓｉｓ Ｊ、 Ｂｅ１
ｌ）の刺傷により主としてヌルデ（Ｒｈｕｓ ｊａｖａ
ｎｌｃａ Ｌｉｎｎｅ ）の葉に生じたゴールである。Gobaishi (Gobaishi) is the aphid (Nurudenomimifushia aphid)
Melaphis chutnensis J, Be1
The sting of Rhus java
This is a gall produced on the leaves of Nlca Linne).
このものは成分として、タンニン５０〜５８％、少量の
没食子酸、脂肪、樹脂等を含み、五倍子チンキ、タンニ
ン酸、没食子酸、ピロガロール等の製造原料として用い
られている。This product contains 50 to 58% tannin, small amounts of gallic acid, fat, resin, etc., and is used as a raw material for producing five-fold tincture, tannic acid, gallic acid, pyrogallol, etc.
上記したように、本発明で用いる生薬ゴバイシは、ヒト
の薬用植物として従来から使用されていたものであるが
、これらを哺乳類および鳥類の疾病の予防及び治療の目
的、殊に哺乳類および鳥類の感染症の予防及び治療の目
的で使用する試み１オこれまでになされたことがなかっ
た。As mentioned above, the herbal medicine Gobaishi used in the present invention has been traditionally used as a medicinal plant for humans. No attempt has been made so far to use it for the purpose of preventing or treating diseases.
本発明者らは、上記したゴバイシの薬効に着目して種々
研究を行なった結果、哺乳類および鳥類がサルモネラ・
ティフィムリウム感染症、即ち細菌Ｓａ１ｍｏｎｅｌｌ
ａ ｔｙｐｈｉａ＋ｕｒｉｕ１１に感染することによっ
て発生する病気の予防及び治療にゴバイシを投与するこ
とがきわめて有効であることを見出して本発明を完成し
たのである。The present inventors conducted various studies focusing on the medicinal effects of gobaishi, and found that mammals and birds are infected with Salmonella.
Typhimurium infection, i.e. the bacterium Sa1monell
The present invention was completed based on the discovery that administering Gobaishi is extremely effective in preventing and treating diseases caused by infection with A. typhia+uriu11.
即ち、下記するように、ゴバイシ及びその抽出物がイン
ビトロ及びインビボにおいて細菌５ａｌｌＯｎｅｌｌａ
ｔｙｐｈｔｍｕｒｔｕＩｌｌに対し特異的に静菌作用
及び殺菌作用があることが明らかになった。That is, as described below, Gobaishi and its extracts are effective against bacteria 5allOnella in vitro and in vivo.
It has been revealed that it has bacteriostatic and bactericidal effects specifically against typhtmurtuIll.
そしてこのＳａｌｍｏｎｅｌｌａ ｔ）ｌｐｈｌｆｆｉ
Ｕｒｉｕｌに対する抑制効果の結果、ゴバイシを哺乳類
や鳥類に投与した場合に、Ｓａｌｍｏｎｅｌｌａ ｔｙ
ｐｈｆｍｕｒｉｕｍに由来する哺乳類、鳥類の疾病であ
るサルモネラ・ティフィムリウム感染症を予防及び冶癒
することができたのである。And this Salmonella t)lphlffi
As a result of the inhibitory effect on Uriul, when Gobaishi is administered to mammals and birds, Salmonella ty
It was possible to prevent and cure Salmonella typhimurium infection, which is a disease of mammals and birds caused by Salmonella phfmurium.
そしてこの哺乳類および鳥類の疾病に対してゴバイシ及
びその抽出物が有効であることは予想もしえなかったこ
とで、本発明者らによってはじめて明らかにされたこと
である。The effectiveness of Gobaishi and its extracts against this disease of mammals and birds was unexpected and was revealed for the first time by the present inventors.
これら生薬は原末そのまま、または抽出エキス、生薬有
効成分の形態で直接投与したり、またこれらのものを飼
料に添加したり、あるいは溶液製剤、分散製剤、半固形
製剤、粉粒体製剤、成型製剤、浸出製剤、注射用製剤等
に製剤化して使用する。These herbal medicines can be directly administered in the form of bulk powder, extracts, or active ingredients of herbal medicines, or added to feed, or can be made into solutions, dispersions, semi-solids, powders, or molded products. It is used in formulations such as preparations, infusion preparations, and injection preparations.
抽出エキスは、例えば、水、有機溶剤または水と有機溶
剤との混合物を使用して溶剤抽出し、それをそのままか
、濃縮してか、希釈してか、または溶剤を除去して用い
られる。The extract is used, for example, by solvent extraction using water, an organic solvent, or a mixture of water and an organic solvent, and used as it is, concentrated, diluted, or after removing the solvent.
有機溶剤としては、例えばメタノール、エタノール、ｎ
−プロパツール、ｎ−ブタノール、アセトン、酢酸エチ
ル、エーテル、塩化メチレン、クロロホルム、ベンゼン
、四塩化炭素、石油エーテル等が使用され、特にメタノ
ール、エタノールが望ましい。これらの有機溶剤は１種
または２種以上の混合物として用いることができる。Examples of organic solvents include methanol, ethanol, n
-Propertool, n-butanol, acetone, ethyl acetate, ether, methylene chloride, chloroform, benzene, carbon tetrachloride, petroleum ether, etc. are used, and methanol and ethanol are particularly preferred. These organic solvents can be used alone or as a mixture of two or more.
この溶剤抽出は、生薬をこれらの溶剤に冷浸または温浸
して行なうことができる。冷浸の場合には１５〜２５℃
、温浸の場合は３５〜４５℃の温度範囲で行なうことが
できる。抽出時間は、抽出温度によって異なるが、一般
的には約５日間または可溶性成分が充分に溶けるまでと
する。This solvent extraction can be carried out by cold soaking or digesting the herbal medicine in these solvents. 15-25℃ for cold soaking
Digestion can be carried out at a temperature range of 35-45°C. The extraction time varies depending on the extraction temperature, but is generally about 5 days or until the soluble components are sufficiently dissolved.
生薬有効成分は、例えば、上記抽出エキスをさらに各種
溶剤を用いて振盪し、この溶剤に移行する画分を採り出
し、その溶剤を留去したものを有効画分、即ち有効成分
として用いることもできる。The active ingredients of herbal medicines can be obtained by, for example, shaking the above-mentioned extract using various solvents, collecting the fraction that migrates to the solvent, and distilling off the solvent, which can be used as the effective fraction, that is, the active ingredient. can.
この場合に使用される溶剤は、非極性溶剤例えば、低級
脂肪族エーテル類（ジエチルエーテル、エチルメチルエ
ーテル等）；低級ハロゲンアルカン類（クロロホルム、
ジクロルエタン、ジブロモエタン等）：ベンゼン類（ベ
ンゼン、トルエン、キシレン等）；その他の石油系溶剤
（石油エーテル、石油ベンゼン、リグロイン等）等が例
としてあげられる。Solvents used in this case include nonpolar solvents such as lower aliphatic ethers (diethyl ether, ethyl methyl ether, etc.); lower halogen alkanes (chloroform, ethyl methyl ether, etc.);
(dichloroethane, dibromoethane, etc.); benzenes (benzene, toluene, xylene, etc.); and other petroleum solvents (petroleum ether, petroleum benzene, ligroin, etc.).
また、この有効画分を採り出した残りの水溶液を、水及
びある種の有機溶剤に水を飽和させたものを使用するこ
とにより振盪抽出し、水洗し、残分である有機溶剤層に
移行する画分の溶剤を留去したものも、有効画分即ち有
効成分として用いることができる。この有効画分は上記
の有効画分とは、物理化学的性質が異なり、検出される
成分も異なるものである。In addition, the remaining aqueous solution from which this effective fraction was extracted is extracted by shaking using water and a kind of organic solvent saturated with water, washed with water, and transferred to the organic solvent layer that is the residue. A fraction obtained by distilling off the solvent can also be used as an effective fraction, that is, an active ingredient. This effective fraction has different physicochemical properties and different detected components from the above-mentioned effective fraction.
投与量は、生薬の原末重量で換算してｏ、ｏｏ１ｍｇ／
体重ｋｇ／日〜１００ｇ／体重ｋｇ／日の範囲である。The dosage is 1 mg/o, oo, converted to the weight of the raw drug powder.
The range is from kg body weight/day to 100 g/kg body weight/day.
この量は予防剤として用いる場合と治療剤として用いる
場合では異なり、一般的には後者の方が投与量は多くな
る。This amount differs depending on whether the drug is used as a prophylactic agent or a therapeutic agent, and the dose is generally higher in the latter case.
投与方法は、経口投与または非経口投与することができ
、非経口投与としては筋肉内投与、腹腔内投与、経皮投
与、経鼻投与、静脈内投与等が可能である。The administration method can be oral or parenteral administration, and examples of parenteral administration include intramuscular administration, intraperitoneal administration, transdermal administration, nasal administration, intravenous administration, and the like.
［発明の効果］
以上詳述したように、本発明によれば哺乳類および鳥類
のサルモネラ・ティフィムリウム感染症の有効な予防及
び治療剤並びに有効な予防及び治療方法が提供される。[Effects of the Invention] As detailed above, the present invention provides an effective preventive and therapeutic agent and an effective preventive and therapeutic method for Salmonella typhimurium infections in mammals and birds.
本発明の予防及び治療剤は生薬またはそれから得られる
エキス等を生薬とするため、抗生物質等の場合の耐性菌
の発生や副作用の問題が全くな（、安心して投与するこ
とができる。Since the prophylactic and therapeutic agent of the present invention uses herbal medicines or extracts obtained from them as herbal medicines, there are no problems of the development of resistant bacteria or side effects associated with antibiotics, etc. (and they can be administered with confidence).
また、薬剤の残留による人体への影響の心配がないため
に、肉用動物に対するサルモネラ・ティフィムリウム感
染症の予防及び治療用の薬物として適当である。Furthermore, since there is no concern about the effects of residual drug on the human body, it is suitable as a drug for preventing and treating Salmonella typhimurium infections in meat animals.
さらに、抗生物質等を用いる場合に比べて、安価に同疾
病を予防及び治療することができる。Furthermore, the disease can be prevented and treated at a lower cost than when using antibiotics or the like.
以下本発明を試験例及び実施例によりさらに詳しく説明
する。The present invention will be explained in more detail below using test examples and examples.
試験例 Ｉ
Ｓａｌｍｏｎｅｌｌａ ｔｙｐｈｉｍｕｒｉｕｍのゴバ
イシに対する感受性を調べた。Test Example I The susceptibility of Salmonella typhimurium to Salmonella typhimurium was investigated.
ゴバイシを、その７倍量の５０％エタノール水溶液中に
加え、１６時間抽出してアルコール抽出物とした。Gobaishi was added to 7 times the amount of 50% ethanol aqueous solution and extracted for 16 hours to obtain an alcoholic extract.
抽出物を直径８ｍｍのディスクに２５μｍずつしみ込ま
せ乾燥させた。このディスクを５ａｌＩＩｏｎｃｌ Ｉ
ａｔｙｐｈｌｍｕｒｉｕｍの菌株を塗ったハート争イン
フュージョン寒天培地に置き３７℃で１８時間培養した
後阻止円の直径を測定したところ、９龍であった。The extract was soaked in 25 μm portions onto a disk with a diameter of 8 mm and dried. This disk is 5alIIoncl I
After culturing at 37° C. for 18 hours on a heart-shaped infusion agar medium coated with a strain of M. atyphlmurium, the diameter of the inhibition circle was measured and found to be 9.
実施例 １
基礎飼料
とうもろこし ３００重量部
マ イ ロ
１３５ 〃ふ す ま
７０〃大 豆 粕 ２
４６〃小 麦 粉 １８０
〃イエローグリス ７ 〃
糖 密 ３０
）ｌ炭酸カルシウム １４．５７１第３り
ん酸カルシウム １１ 〃食
塩 ５ 〃ビタミン・ミル
ラル剤 １．５”前記基礎飼料にゴバイシ
粉末を重量比で０．５％添加し、供試飼料とした。この
供試飼料を３０日令の牛２０頭に自由に摂餌させた。試
験開始より５日目にＳａｌｍｏｎｃｌｌａ ｔｙｐｈｌ
Ｉｌｕｒｉｕ＊を１頭当り５Ｘ１０９個／ｍ１／頭経口
投与した。また対照区は供試飼料の代わりに前記基礎飼
料を与えた。そして菌を経口投与してから１０日後まで
の５ａｌｓｏｎｅｌ Ｉａｔｙｐｈｉｍｕｒｌｕｍによ
る下痢の発生を観察した。Example 1 Basic feed corn 300 parts by weight
135
70 Soybean meal 2
46〃Wheat flour 180
〃Yellow grease 7〃 Sugar dense 30
) l Calcium carbonate 14.571 Tertiary calcium phosphate 11 Food
Salt 5 Vitamin/Mirral preparation 1.5" Gobaishi powder was added at 0.5% by weight to the above basal feed to prepare a test feed. This test feed was fed ad libitum to 20 30-day-old cows. On the 5th day from the start of the test, Salmonclla typhl
Iluriu* was orally administered at 5×109 cells/ml/head per animal. In addition, the control group was given the above basal feed instead of the test feed. The occurrence of diarrhea caused by 5alsonel Iatyphimurrum was observed up to 10 days after oral administration of the bacteria.
その結果感染後にＳａｌｍｏｎｅｌｌａ ｔｙｐｈｉｍ
ｕｒｉｕｍにより下痢を起こした牛は本発明の試験区で
は１頭であったが対照区は１３頭であった。As a result, after infection Salmonella typhi
The number of cows who developed diarrhea due to urium was one in the test plot of the present invention, but 13 in the control plot.
実施例 ２
ゴバイシ１ ｋｇをとり、これをＩＯＪの水に入れ１０
０℃で１時間抽出した。この水抽出物を１０００倍に希
釈し抽出エキスとした。３０口日の健康な牛を２０頭使
用し抽出エキスを水の代わりに給与した。Example 2 Take 1 kg of gobaishi and put it in IOJ water for 10 minutes.
Extraction was performed at 0°C for 1 hour. This aqueous extract was diluted 1000 times to obtain an extract. Twenty 30-day-old healthy cows were used and the extract was fed in place of water.
飼料は実施例１で使用したものと同じ基礎飼料を用いた
。また対照区は水抽出物の代わりに水を与えた。試験開
始から５日目にＳａｌ■ｏｎｅｌ Ｉａｔｙｐｈｉａｕ
ｒｌｕｌｌを５Ｘ１０９個／ ｍｌ ／頭経口投与して
感染させた。菌を経口投与後１０日目迄に５ａｌｏ＋ｏ
ｎｅｌ Ｉａ Ｌｙｐｈｉｍｕｒｉｕｍにより下痢の症
状を示した牛の頭数を調べた結果本発明の試験区は対照
区より少なかった。The same basal feed as that used in Example 1 was used as the feed. In the control group, water was given instead of the water extract. Salonel Iatyphiau on the 5th day from the start of the test
The animals were infected by oral administration of 5×109 cells/ml/head. 5alo+o by 10th day after oral administration of bacteria
As a result of investigating the number of cows that showed symptoms of diarrhea due to Nel Ia Lyphimurium, the test plots of the present invention were smaller than the control plots.
特許出願人 Ｌ、Ｉ清製粉株式会社Patent applicant: L, I Seifun Co., Ltd.
Claims (1)
・ティフィムリウム感染症の予防及び治療剤。 ２）ゴバイシが、原末の形態である特許請求の範囲第１
項に記載の予防及び治療剤。 ３）ゴバイシが有機溶剤、水と有機溶剤との混合物また
はそれから得られた有効成分である特許請求の範囲第１
項に記載の予防及び治療剤。 ４）ゴバイシが、飼料中に配合されてなる特許請求の範
囲第１項に記載の予防及び治療剤。 ５）哺乳類および鳥類が牛、豚、マウス、鶏である特許
請求の範囲第１項に記載の予防及び治療剤。 ６）有効量のゴバイシを投与することからなる哺乳類お
よび鳥類のサルモネラ・ティフィムリウム感染症の予防
及び治療方法。 ７）ゴバイシが原末の形態で用いられる特許請求の範囲
第６項に記載の予防及び治療方法。 ８）ゴバイシが有機溶剤、水と有機溶剤との混合物また
は水で抽出したゴバイシエキス及び／またはそれから得
られた有効成分として用いられる特許請求の範囲第６項
に記載の予防及び治療方法。 ９）ゴバイシが飼料に混合して投与される特許請求の範
囲第６項に記載の予防及び治療方法。 １０）哺乳類および鳥類が、牛、豚、マウス、鶏である
特許請求の範囲第６項に記載の予防及び治療方法。[Scope of Claims] 1) A prophylactic and therapeutic agent for Salmonella typhimurium infection in mammals and birds, containing Gobaishi. 2) Claim 1 in which Gobaishi is in the form of bulk powder
Prophylactic and therapeutic agents as described in Section. 3) Claim 1 in which the gobaisai is an organic solvent, a mixture of water and an organic solvent, or an active ingredient obtained therefrom.
Prophylactic and therapeutic agents as described in Section. 4) The prophylactic and therapeutic agent according to claim 1, wherein Gobaishi is blended in feed. 5) The prophylactic and therapeutic agent according to claim 1, wherein the mammals and birds are cows, pigs, mice, and chickens. 6) A method for preventing and treating Salmonella typhimurium infections in mammals and birds, which comprises administering an effective amount of Gobaishi. 7) The prevention and treatment method according to claim 6, wherein Gobaishi is used in the form of bulk powder. 8) The preventive and therapeutic method according to claim 6, wherein Gobaishi is used as an organic solvent, a mixture of water and an organic solvent, or a water-extracted Gobaishi extract and/or an active ingredient obtained therefrom. 9) The preventive and therapeutic method according to claim 6, wherein Gobaishi is mixed with feed and administered. 10) The prevention and treatment method according to claim 6, wherein the mammal and bird are cows, pigs, mice, and chickens.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62328333A JP2599163B2 (en) | 1987-12-26 | 1987-12-26 | Prevention and treatment of Salmonella tefimurium infection in livestock and poultry |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62328333A JP2599163B2 (en) | 1987-12-26 | 1987-12-26 | Prevention and treatment of Salmonella tefimurium infection in livestock and poultry |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01172330A true JPH01172330A (en) | 1989-07-07 |
| JP2599163B2 JP2599163B2 (en) | 1997-04-09 |
Family
ID=18209061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62328333A Expired - Lifetime JP2599163B2 (en) | 1987-12-26 | 1987-12-26 | Prevention and treatment of Salmonella tefimurium infection in livestock and poultry |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2599163B2 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100267490B1 (en) * | 1997-12-23 | 2000-10-16 | 안용준 | Novel Healthy food additive |
| KR100839099B1 (en) * | 2007-03-08 | 2008-06-19 | 원광대학교산학협력단 | Composition comprising an extract of galla rhois and moutan cortex radicis for preventing and treating the porcine epidemic diarrhea virus(pedv) |
| WO2012144754A2 (en) * | 2011-04-19 | 2012-10-26 | 원광대학교 산학협력단 | Composition containing a galla rhois extract having virus inhibitory effects or a compound isolated therefrom as an active ingredient, and uses thereof |
| KR101369255B1 (en) * | 2007-03-16 | 2014-03-05 | 원광대학교산학협력단 | A veterinary composition comprising extracts of Galla Rhois and Moutan Cortex Radicis showing antibacterial and antiviral activity |
| US11000050B2 (en) | 2015-10-09 | 2021-05-11 | Axichem Ab | Bird feed and in particular poultry feed, comprising synthetic capsaicinoid derivatives and such feed for prophylactic use or treatment of Salmonella infection |
-
1987
- 1987-12-26 JP JP62328333A patent/JP2599163B2/en not_active Expired - Lifetime
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100267490B1 (en) * | 1997-12-23 | 2000-10-16 | 안용준 | Novel Healthy food additive |
| KR100839099B1 (en) * | 2007-03-08 | 2008-06-19 | 원광대학교산학협력단 | Composition comprising an extract of galla rhois and moutan cortex radicis for preventing and treating the porcine epidemic diarrhea virus(pedv) |
| KR101369255B1 (en) * | 2007-03-16 | 2014-03-05 | 원광대학교산학협력단 | A veterinary composition comprising extracts of Galla Rhois and Moutan Cortex Radicis showing antibacterial and antiviral activity |
| WO2012144754A2 (en) * | 2011-04-19 | 2012-10-26 | 원광대학교 산학협력단 | Composition containing a galla rhois extract having virus inhibitory effects or a compound isolated therefrom as an active ingredient, and uses thereof |
| WO2012144754A3 (en) * | 2011-04-19 | 2013-01-10 | 원광대학교 산학협력단 | Composition containing a galla rhois extract having virus inhibitory effects or a compound isolated therefrom as an active ingredient, and uses thereof |
| US11000050B2 (en) | 2015-10-09 | 2021-05-11 | Axichem Ab | Bird feed and in particular poultry feed, comprising synthetic capsaicinoid derivatives and such feed for prophylactic use or treatment of Salmonella infection |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2599163B2 (en) | 1997-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abad et al. | Effect of Salvia officinalis hydroalcoholic extract on vincristine-induced neuropathy in mice | |
| JP2599159B2 (en) | Prevention and treatment of bovine mastitis | |
| Yadav et al. | Anthelmintic and Antibacterial Activity of Psidium Guajava Leaf Extracts | |
| JP2603977B2 (en) | Prevention and treatment of Pasteurella haemolytica infection in livestock | |
| JPH01172330A (en) | Preventive and remedy for infectious disease of salmonella typhimurium of mammals and birds | |
| JPH01172333A (en) | Preventive and remedy for swine infectious diseases of streptococcus hemolyticus | |
| CN100367989C (en) | Medication for treating disease of alimentary tract of livestock husbandry and birds | |
| JP2535554B2 (en) | Preventive and therapeutic agent for edwadiella infection in fish | |
| JP2599160B2 (en) | Preventive and therapeutic agent for staphylococcal disease in chickens | |
| Shree et al. | Pharmacological and phytochemical evaluation of anti-ulcerogenic potential of Solanum nigrum | |
| JP2599158B2 (en) | Prevention and treatment of Campylobacter jejuni infection in livestock | |
| JP2535553B2 (en) | Agent for preventing and treating bacterial nodule disease in fish | |
| JP2535557B2 (en) | Agent for preventing and treating Vibrio alderi infection of fish | |
| JP2599162B2 (en) | Prevention and treatment of Salmonella enteritidis infection in livestock and poultry | |
| JP2535558B2 (en) | Agent for prevention and treatment of fin fin disease of fish | |
| JPH01172334A (en) | Preventive and remedy for swine pasteurellosis | |
| JP2599157B2 (en) | Preventive and therapeutic agent for swine dysentery | |
| CN107307214B (en) | A kind of feed addictive for treating diarrhea of pigs | |
| JP2599155B2 (en) | Prevention and treatment of avian colibacillosis | |
| JP2599156B2 (en) | Preventive and therapeutic agent for Corynebacterium renale infection in livestock | |
| JP2535556B2 (en) | Agent for prevention and treatment of vibrio disease in fish | |
| JP2599154B2 (en) | Agent for prevention and treatment of haemophilus infection in pigs | |
| JP2599153B2 (en) | Preventive and therapeutic agent for pordetosis in pigs | |
| CN104688883B (en) | A kind of Chinese medicine composition of kuh-seng containing wolf's milk and radix scutellariae and preparation method thereof | |
| Tharakan et al. | Effect of AC II, a herbal formulation on radiation-induced immunosuppression in mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |